Objetivo
Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SCID) have been successfully treated by autologous stem cell based gene therapy. However, for the most common group of SCID, the SCID underlying recombination defects, this has not yet occurred due to the higher complexities of the affected genes involved. The aim of the current proposal is to fill the unmet medical need for the most common major category of SCID, recombination activating gene-1 (RAG-1) deficient SCID, by performing Stage I/II clinical trials using autologous hematopoietic stem cell based gene therapy. To this end we will develop novel safety assays, pre-GMP and GMP lentiviral batches and design and conduct multicenter, multinational clinical trials with input from regulatory authorities such as EMA and patient advocacy groups. The trial will be conducted with phenotypic, molecular (integration sites, therapeutic gene expression) and functional readouts and should lead to effective treatment for > 70% of all SCID patients in Europe. RECOMB forms the logical extension of highly successful previous EU consortia that have made the EU global leader in gene therapy for orphan immune diseases.
Ámbito científico
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineemergency medicinegraft versus host disease
- medical and health sciencesclinical medicinetransplantation
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2017-Two-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
2333 ZA Leiden
Países Bajos
Ver en el mapa
Participantes (16)
75654 Paris
Ver en el mapa
WC1E 6BT London
Ver en el mapa
WC1N 3JH London
Ver en el mapa
20132 Milano
Ver en el mapa
30625 Hannover
Ver en el mapa
89081 Ulm
Ver en el mapa
50 367 Wroclaw
Ver en el mapa
NE1 7RU Newcastle Upon Tyne
Ver en el mapa
PL11 3LE Torpoint
Ver en el mapa
2333 CL Leiden
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
08035 Barcelona
Ver en el mapa
00165 Roma
Ver en el mapa
75012 Paris
Ver en el mapa
52621 Ramat Gan
Ver en el mapa
80539 MUNCHEN
Ver en el mapa
69120 Heidelberg
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.